Abstract:ObjectivePreeclampsia is a condition arising from poor placentation and manifests itself as hypertension and proteinuria later in pregnancy. There are currently no specific laboratory based tests to diagnose preeclampsia for timely management or use of interventions. As a result, preeclampsia is a leading cause of preterm birth as well as maternal and fetal death. Our objective is to develop a serological protein assay to allow early recognition and referral of preeclamptic patients to Maternal Fetal Medicine specialists.Study DesignCandidate biomarkers were revealed by ensemble analysis of gene expression and proteomics profiling of preeclampsia samples. Biomarkers were further qualified with enzyme-linked immunosorbent assays (ELISA) using serum samples from 33 preeclampsia subjects and 31 pregnant controls matched by parity, ethnicity, and gestational age (range 24-40 weeks). A five-protein serological panel, comprised of both novel and investigational proteins, was constructed by the application of a genetic algorithm optimized for its ability to accurately diagnose preeclampsia as defined by the area under the receiving operating characteristic curve.ResultsWe observed better clustering and separation between samples from preeclamptic and non-preeclamptic patients compared to previously described, investigational diagnostic tests. Separation between patients groups was more pronounced earlier in gestational age.ConclusionWe have identified a serological protein panel capable of diagnosing both early and late onset preeclampsia. Further characterization of the novel panel analytes yielded mechanistic insights in preeclampsia, therefore, explaining the observed sensitivity and specificity across gestational ages. Future prospective validation can drive the translation of our serological panel into practical bedside clinical utilities for preeclampsia care. The work was supported by grants from the March of Dimes and Stanford University Spark Program. ObjectivePreeclampsia is a condition arising from poor placentation and manifests itself as hypertension and proteinuria later in pregnancy. There are currently no specific laboratory based tests to diagnose preeclampsia for timely management or use of interventions. As a result, preeclampsia is a leading cause of preterm birth as well as maternal and fetal death. Our objective is to develop a serological protein assay to allow early recognition and referral of preeclamptic patients to Maternal Fetal Medicine specialists. Preeclampsia is a condition arising from poor placentation and manifests itself as hypertension and proteinuria later in pregnancy. There are currently no specific laboratory based tests to diagnose preeclampsia for timely management or use of interventions. As a result, preeclampsia is a leading cause of preterm birth as well as maternal and fetal death. Our objective is to develop a serological protein assay to allow early recognition and referral of preeclamptic patients to Maternal Fetal Medicine specialists. Study DesignCandidate biomarkers were revealed by ensemble analysis of gene expression and proteomics profiling of preeclampsia samples. Biomarkers were further qualified with enzyme-linked immunosorbent assays (ELISA) using serum samples from 33 preeclampsia subjects and 31 pregnant controls matched by parity, ethnicity, and gestational age (range 24-40 weeks). A five-protein serological panel, comprised of both novel and investigational proteins, was constructed by the application of a genetic algorithm optimized for its ability to accurately diagnose preeclampsia as defined by the area under the receiving operating characteristic curve. Candidate biomarkers were revealed by ensemble analysis of gene expression and proteomics profiling of preeclampsia samples. Biomarkers were further qualified with enzyme-linked immunosorbent assays (ELISA) using serum samples from 33 preeclampsia subjects and 31 pregnant controls matched by parity, ethnicity, and gestational age (range 24-40 weeks). A five-protein serological panel, comprised of both novel and investigational proteins, was constructed by the application of a genetic algorithm optimized for its ability to accurately diagnose preeclampsia as defined by the area under the receiving operating characteristic curve. ResultsWe observed better clustering and separation between samples from preeclamptic and non-preeclamptic patients compared to previously described, investigational diagnostic tests. Separation between patients groups was more pronounced earlier in gestational age. We observed better clustering and separation between samples from preeclamptic and non-preeclamptic patients compared to previously described, investigational diagnostic tests. Separation between patients groups was more pronounced earlier in gestational age. ConclusionWe have identified a serological protein panel capable of diagnosing both early and late onset preeclampsia. Further characterization of the novel panel analytes yielded mechanistic insights in preeclampsia, therefore, explaining the observed sensitivity and specificity across gestational ages. Future prospective validation can drive the translation of our serological panel into practical bedside clinical utilities for preeclampsia care. The work was supported by grants from the March of Dimes and Stanford University Spark Program. We have identified a serological protein panel capable of diagnosing both early and late onset preeclampsia. Further characterization of the novel panel analytes yielded mechanistic insights in preeclampsia, therefore, explaining the observed sensitivity and specificity across gestational ages. Future prospective validation can drive the translation of our serological panel into practical bedside clinical utilities for preeclampsia care. The work was supported by grants from the March of Dimes and Stanford University Spark Program.

642: Transcriptomics and Proteomics Ensemble Analyses Reveal Serological Protein Panel for Preeclampsia Diagnosis

Integrating Multiple ‘omics’ Analyses Identifies Serological Protein Biomarkers for Preeclampsia

Serum Protein Marker Panel for Predicting Preeclampsia.

Mass Spectrometry-Based Proteomics for Pre-Eclampsia and Preterm Birth

Late first trimester circulating microparticle proteins predict the risk of preeclampsia < 35 weeks and suggest phenotypic differences among affected cases

Parallel Assessment Of Circulatory Fetal Dna And Corticotropin-Releasing Hormone Mrna In Early- And Late-Onset Preeclampsia

Serum peptidomic screening identified circulating peptide biomarkers predictive for preeclampsia

Integration of Single-Cell Sequencing and Transcriptomic Analysis to Identify Novel Diagnostic Biomarkers for Preeclampsia and Explore Changes in Immune Cell Interactions

Proteomic analysis of human serum for Finding pathogenic factors and potential biomarkers in preeclampsia

Protein Profiling Of Preeclampsia Placental Tissues

Proteomic Profiles of Maternal Plasma Extracellular Vesicles for Prediction of Preeclampsia

Epigenetic phenotype of plasma cell-free DNA in the prediction of early-onset preeclampsia

Proteome- and Transcriptome-Wide Genetic Analysis Identifies Biological Pathways and Candidate Drug Targets for Preeclampsia

First-Trimester Preeclampsia-Induced Disturbance in Maternal Blood Serum Proteome: A Pilot Study

Serum proteins differentially expressed in early- and late-onset preeclampsia assessed using iTRAQ proteomics and bioinformatics analyses

Peptidomic Identification of Serum Peptides Diagnosing Preeclampsia

Maternal plasma proteome profiling of biomarkers and pathogenic mechanisms of early-onset and late-onset preeclampsia

Proteomic profile of preeclampsia in the first trimester of pregnancy

A cross-sectional analysis of syncytiotrophoblast membrane extracellular vesicles-derived transcriptomic biomarkers in early-onset preeclampsia

Distinct cytokine profiles in patients with preeclampsia

Proteomic Analysis Reveals Differential Protein Expression in Placental Tissues of Early-Onset Preeclampsia Patients